A phase I/IIa trial of [212Pb]VMT01 MC1R-targeted alpha-particle mono- and combination-therapy with nivolumab in participants with previously treated unresectable or metastatic melanoma (SITC 2026) - Oct 2, 2026 - Abstract #571; Pres time: Nov 6, 2026; 10:00 AM - 07:00 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available
Combination therapy • Metastases • P1/2 data • Melanoma • Oncology • Solid Tumor
|
|
Matthew Block; Zachary Morris; Jose Lutzky; Richard Wahl; Anthony Olszanski; Yusuf Menda; Samuel Mehr; Markus Puhlmann; Lucia Baratto; Sam Ayuk; Alaa Hanna; Debbie Pomponio; Ravi Patel; Ruta Arays
|